BAYER AG

Discover how Bayer’s glyphosate settlement and Perfuse Therapeutics acquisition boost risk‑mitigation and ophthalmology growth, sparking modest share gains.

Update: Bayer AG faces new U.S. lawsuit, remains compliant with regulations, and is working with legal counsel to protect shareholders without immediate operational impact.

Discover how Bayer’s lawsuit over NK603 corn seeds could reshape U.S. agricultural markets, impact farmer costs, and influence food prices and public health.

Explore how Bayer AG balances stable drug sales with bold pipeline expansions into rare disease and personalized oncology, navigating market volatility while aiming for long‑term value.

Explore how Bayer AG’s earnings beat and FDA priority‑review of its stroke‑prevention drug BAY‑S12 are driving market gains and promising earlier, cost‑effective stroke care.

Explore how Bayer AG’s new shareholder ID updates, treasury share cuts, and AI‑powered commercial talks reveal its sharp focus on governance, capital efficiency, and digital strategy.

Explore how Bayer AG’s Crop Science unit drives 2026 growth, from gene‑edited crops to AI irrigation, while boosting yields and community impact.

Explore Bayer AG’s Q1 2026 results: Crop Science’s €3.1bn revenue surge, Pharma’s patent‑cliff strategy, and a €7bn legal settlement’s impact on earnings.

Read how Bayer’s shares slipped ahead of a U.S. glyphosate trial, with investors weighing potential settlements and the broader market’s geopolitical backdrop.

How the Supreme Court’s Roundup ruling could cost Bayer AG $3‑$5 bn, shift agro‑chemical regulation and raise healthcare supply‑chain costs.